Shares for Amgen have remained relatively stable amid news that sales of a rival drug would be allowed and a cash and stock partnership deal with Bay Area-based CytomX. The Thousand Oaks biotech giant partnered up with Bay Area-based CytomX Therapeutics to develop an anti-cancer drug, purchasing $20 million of its common stock. Two days…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
